IRIS
ARMUZZI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.436
EU - Europa 1.774
AS - Asia 992
AF - Africa 74
SA - Sud America 4
OC - Oceania 1
Totale 9.281
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.416
FI - Finlandia 530
SG - Singapore 521
IE - Irlanda 413
CN - Cina 274
FR - Francia 214
DE - Germania 174
NL - Olanda 119
IN - India 116
GB - Regno Unito 78
NG - Nigeria 69
IT - Italia 59
RU - Federazione Russa 45
SE - Svezia 42
BE - Belgio 34
CZ - Repubblica Ceca 25
IR - Iran 21
CA - Canada 18
HK - Hong Kong 14
TR - Turchia 13
IL - Israele 11
JP - Giappone 10
AT - Austria 5
EG - Egitto 5
LT - Lituania 5
RO - Romania 5
ES - Italia 4
PK - Pakistan 4
BG - Bulgaria 3
BR - Brasile 3
CH - Svizzera 3
PL - Polonia 3
AE - Emirati Arabi Uniti 2
EE - Estonia 2
MX - Messico 2
PH - Filippine 2
TW - Taiwan 2
UA - Ucraina 2
AR - Argentina 1
AU - Australia 1
BN - Brunei Darussalam 1
DK - Danimarca 1
GR - Grecia 1
IS - Islanda 1
LU - Lussemburgo 1
MK - Macedonia 1
NO - Norvegia 1
PT - Portogallo 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
VN - Vietnam 1
Totale 9.281
Salva come PNG Salva come JPEG
Città #
Chandler 1.802
Helsinki 529
Dublin 413
Ashburn 397
Boardman 397
Lawrence 390
Princeton 390
Singapore 387
Shanghai 249
New York 213
Paris 206
Wilmington 184
Amsterdam 119
Los Angeles 115
Pune 110
London 71
Benin City 68
San Mateo 65
Ann Arbor 49
Seattle 46
Santa Clara 39
Moscow 35
Brussels 33
Phoenix 32
Leawood 29
Brno 22
Fairfield 19
Munich 19
Woodbridge 19
Frankfurt am Main 17
Toronto 14
Oshnaviyeh 12
Falkenstein 11
Berlin 9
Milan 9
Kocaeli 8
Hanover 6
Hong Kong 6
Beijing 5
Clifton 5
Collegeville 5
Council Bluffs 5
Norwalk 5
St Petersburg 5
Tokyo 5
Campobasso 4
Miami 4
Redwood City 4
Vienna 4
Atlanta 3
Bologna 3
Cambridge 3
Hirakata 3
Houston 3
Irsina 3
Madrid 3
Olomouc 3
Ottawa 3
Rome 3
San Francisco 3
Sassari 3
Sofia 3
São Paulo 3
Tel Aviv 3
Cairo 2
Cinisello Balsamo 2
Genoa 2
Hadera 2
Hangzhou 2
Istanbul 2
Iztapalapa 2
Las Vegas 2
Montichiari 2
Mumbai 2
Paulding 2
Qingdao 2
Sale Marasino 2
Stockholm 2
Tallinn 2
Toulouse 2
Turin 2
Warsaw 2
Évry 2
Assiut 1
Augusta 1
Bandar Seri Begawan 1
Bareggio 1
Belgrade 1
Bitola 1
Buenos Aires 1
Buffalo 1
Camerino 1
Cary 1
Chennai 1
Chicago 1
Clearwater 1
Copenhagen 1
Craiova 1
Dalsjoefors 1
Damietta 1
Totale 6.690
Salva come PNG Salva come JPEG
Nome #
A liophylized and inactivated colture of Lactobacillus acidophilus increases Helicobacter pylori eradication rate 64
Adalimumab in active ulcerative colitis: A "real-life" observational study 59
13C-breath tests in the study of mitochondrial liver function 56
13C-Breath Tests in the study of microsomal liver function 54
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 52
Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease 51
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 47
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting 47
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial 46
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management 45
Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative Colitis 44
Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study 44
Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease 43
FOXP3(+) T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF alpha Agents 43
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission 41
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates 40
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 40
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment 40
Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study 39
H-pylori poliantibiotic resistant strains in dyspeptic patients not eradicated by two consecutive triple eradication regimens 39
Acute pancreatitis and parathyroid carcinoma: a case report and literature review 38
A transition clinic model for inflammatory bowel disease between two tertiary care centers: outcomes and predictive factors 38
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar 38
The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases 37
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease 37
Long-term scheduled therapy with infliximab in inflammatory bowel disease 37
Difference in treatment outcomes between clinical trials and "real-life" clinical practice: ustekinumab in ulcerative colitis 37
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 37
ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment 37
H-pylori gastric infection and rheumatic diseases 36
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 36
3-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure H-pylori infection 36
Role of helicobacter pylori in gastroesophageal reflux disease 36
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 36
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 36
The intercellular adhesion molecule-1 polymorphisms in IBD 35
HELICOBACTER-PYLORI GASTRITIS WITH CYTOTOXIN ASSOCIATED PROTEIN ANTIBODIES (CAGA) - A COMPUTER-AIDED EVALUATION OF INFLAMMATORY CELL INFILTRATION IN THE LAMINA PROPRIA, ATROPHIC GASTRITIS AND ACQUIRED MALT 35
Disease patterns in late-onset ulcerative colitis: Results from the " IG-IBD ""AGED study""" 35
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 34
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders 34
Helicobacter pylori eradication ameliorates migraine: An extended follow up study 34
Anti-CagA antibodies are associated with atrophic gastritis in a population at high gastric cancer risk: a morphometric study by computerized image analysis 34
Adherence to international guidelines for the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in Italy: A Survey of the Italian Federation of Digestive Diseases - FISMAD 34
C-13-methionine breath tests for mitochondrial liver function assessment 33
Infliximab in Steroid-Dependent Ulcerative Colitis 33
New biological agents for the treatment of the "high risk" IBD patients 33
Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease 33
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 32
Advances in extracorporeal detoxification by MARS dialysis in patients with liver failure 32
Fecal calprotection in first-degree relatives of patients with ulcerative colitis 32
Aminopyrine and methacetin 13C-breath tests to assess hepatic function in HCV-related chronic liver disease 32
Antibiotic resistance of H-pylori strains obtained by dyspeptic patients not eradicated by two consecutive eradication regimens 32
C-13-methacetin breath test in patients with nonalcoholic steatohepatitis 32
Long-Term Scheduled Therapy with Infliximab in Inflammatory Bowel Disease 32
Efficacy of a multistep strategy for Helicobacter pylori eradication 32
C-13 urea breath test for predicting resistance to therapy in Helicobacter pylori infection 32
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results 32
Activity of Crohn's disease and small bowel contract-enhanced ultrasound findings 32
Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study 32
Young GI angle: Should I go abroad? 31
INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS ON ANTI TNF-ALPHA THERAPY: RESPONSE TO THE INFLUENZA A/H1N1 VACCINE 31
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study 31
Diet and Nutrients in Gastrointestinal Chronic Diseases 31
Complex Perianal Crohn's Disease: Effectiveness of Combined Seton Placement and Anti-TNF Alpha Agents in Monotherapy or in Association With Immunosuppressants 31
Adalimumab in the treatment of immune-mediated diseases 31
Hepatic mitochondrial beta-oxidation in patients with Nonalcoholic-Steatohepatitis (NASH) assessed by 13C-octanoate breath test 31
A novel pathogenic role for microvasculature in inflammatory bowel disease 31
Mono, dual and triple moxifloxacin-based regimens for Helicobacter pylori eradication 31
Dual Targeted Therapy in Patient With Extensive Crohn's Disease: Different Response at Distinct Location 31
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG-IBD study 31
Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign 31
Gender affects C-13-ketoisocaproic acid breath test 30
COMPLEX PERIANAL FISTULIZING CROHN'S DISEASE: LONG-TERM EFFICACY OF COMBINED SETON PLACEMENT AND ANTI TNF-ALPHA AGENTS ALONE OR ASSOCIATED WITH IMMUNOSUPPRESSANTS 30
COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patients' Association 30
The management of inflammatory bowel diseases in the era of COVID-19 pandemic: When "non-urgent" does not mean "deferrable" 30
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study 30
Helicobacter pylori-related diseases 30
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 30
Reply to Dr. Kotze's and Dr. Yamamoto's letter 30
Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients 30
anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab 30
Non-invasive assessment of human hepatic mitochondrial function through the C-13-methionine breath test 30
Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study 29
Incidence and symptoms related to Helicobacter pylori infection in dyspeptic patients 29
Haplotypic analysis of heat shock protein 70 (HSP70) single nucleotide polymorphisms (SNPs) in susceptibility and phenotype of inflammatory bowel disease (IBD) 29
New developments in biologics therapy: what about from the medical point of view? 29
Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study 29
Hepatic mitochondrial function assessment through C-13-methionine and C-13-sodium octanoate breath tests 29
Levofloxacin based regimens for the eradication of Helicobacter pylori 29
Usefulness of C-13-methionine breath test as a non-invasive and dynamic tool to evaluate residual hepatic mitochondrial function 29
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 29
Insulin-dependent diabetes mellitus affects eradication rate of Helicobacter pylori infection 29
Gender affects 13C-ketoisocaproic breath test for liver mitochondrial function 29
Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery? 29
Study of liver function in healthy elderly subjects using the C-13-methacetin breath test 29
Role of sucralfate in gastrointestinal diseases 29
Update on the management of inflammatory bowel disease: specific role of adalimumab 29
DISAPPEARANCE OF GASTRIC ACQUIRED MALT AND REGRESSION OF LOW-GRADE B-CLL GASTRIC LYMPHOMA BY MEAN ANTI-H-PYLORI TREATMENT 29
Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open 29
Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease 29
Totale 3.501
Salva come PNG Salva come JPEG
Categoria #
all - tutte 89.589
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.589
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20209 0 0 0 0 0 0 0 0 0 0 0 9
2020/2021334 2 3 1 4 0 114 41 21 74 42 1 31
2021/2022227 6 2 11 43 3 0 7 24 19 19 50 43
2022/20235.208 842 55 423 571 430 547 7 531 960 455 333 54
2023/20243.336 219 318 781 260 112 383 184 108 26 217 337 391
2024/2025263 95 27 49 56 36 0 0 0 0 0 0 0
Totale 9.377